Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Profound Medical ( (TSE:PRN) ) just unveiled an announcement.
Profound Medical Corp., a commercial-stage medical device company specializing in interventional MRI procedures and minimally invasive treatments such as its TULSA-PRO and Sonalleve platforms, reported on February 12, 2026, that it continues to expand applications of its technologies across prostate disease and certain benign and cancer-related indications worldwide. The company noted that TULSA-PRO holds CE marking, Health Canada approval and U.S. FDA 510(k) clearance, while Sonalleve is CE marked, approved in China for uterine fibroids and has U.S. FDA Humanitarian Device Exemption approval for osteoid osteoma, underscoring its progressing regulatory and commercial positioning.
On February 12, 2026, Profound announced plans to release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026, followed by a management-hosted conference call at 4:30 p.m. ET to review results and discuss business developments. The webcast of the March 5 call will be available live and archived in the investors section of the company’s website, offering stakeholders an opportunity to assess recent performance and operational progress.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held back primarily by persistent heavy losses and large cash burn despite strong revenue growth and improving gross margins. Technicals are supportive with a clear uptrend, and recent earnings commentary and events point to improving commercial traction and strengthened liquidity, but financing/dilution risk and lack of profitable valuation anchors keep the overall score in the mid-range.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that develops and markets innovative interventional MRI procedures, with a focus on minimally invasive treatments for prostate disease and certain benign and cancerous conditions. Its key products include TULSA-PRO, used for the incision- and radiation-free TULSA Procedure across the prostate disease spectrum, and Sonalleve, a therapeutic platform for non-invasive treatment of uterine fibroids, adenomyosis, bone metastases pain, desmoid tumors and osteoid osteoma.
Average Trading Volume: 20,855
Technical Sentiment Signal: Sell
Current Market Cap: C$312.8M
Find detailed analytics on PRN stock on TipRanks’ Stock Analysis page.